Journal of Circulating Biomarkers (Apr 2016)

Elevated Adiponectin Antibody Levels in Sera of Patients with Atherosclerosis-Related Coronary Artery Disease, Cerebral Infarction and Diabetes Mellitus

  • Takaki Hiwasa,
  • Xiao-Meng Zhang,
  • Risa Kimura,
  • Mikiko Ohno,
  • Po-Min Chen,
  • Eiichiro Nishi,
  • Koh Ono,
  • Takeshi Kimura,
  • Ikuo Kamitsukasa,
  • Takeshi Wada,
  • Akiyo Aotsuka,
  • Seiichiro Mine,
  • Hirotaka Takizawa,
  • Koichi Kashiwado,
  • Minoru Takemoto,
  • Kazuki Kobayashi,
  • Harukiyo Kawamura,
  • Ryoichi Ishibashi,
  • Koutaro Yokote,
  • Rika Nakamura,
  • Go Tomiyoshi,
  • Natsuko Shinmen,
  • Hideyuki Kuroda

Journal volume & issue
Vol. 5

Abstract

Read online

Adiponectin secreted from the adipocytes plays pleiotropic, anti-atherosclerotic roles, such as enhancement of insulin secretion and an increase in energy expenditure. The measurement of levels of circulating adiponectin is useful to evaluate the progression of atherosclerosis-related diseases, such as coronary artery disease (CAD), cerebral infarction (CI) and diabetes mellitus (DM). We examined the serum antibody levels against recombinant adiponectin protein via the amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA) method. The results revealed that the antibody levels were significantly higher in patients with CAD, CI and type 2 DM, than in healthy donors. Receiver operating curve analysis showed that the sensitivity was in a range of 41–48% for CAD, CI and DM. Thus, the serum anti-adiponectin antibody levels could be a common marker for atherosclerosis-related diseases.